---
title: "STERIS plc SEC 10-Q Report"
date: "2025-02-08 05:43:01"
summary: "STERIS plc, a leading provider of infection prevention and other procedural products and services, has released its latest Form 10-Q report, showcasing robust financial and operational performance for the recent quarter. The report highlights significant growth in revenues, improved profitability, and strategic business developments that position the company for continued..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

STERIS plc, a leading provider of infection prevention and other procedural products and services, has released its latest Form 10-Q report, showcasing robust financial and operational performance for the recent quarter. The report highlights significant growth in revenues, improved profitability, and strategic business developments that position the company for continued success in the healthcare and life sciences sectors.

**Financial Highlights**

**Total Revenues**: $1,370.6 million, reflecting an increase from $1,297.7 million in the same period last year, driven by growth in both Product and Service revenues.

**Gross Profit**: $610.3 million, up from $560.0 million in the prior year, indicating improved cost management and operational efficiency.

**Income from Operations**: $245.3 million, compared to $226.5 million in the previous year, highlighting effective cost control and increased revenue.

**Net Income**: $173.3 million, an increase from $140.9 million last year, benefiting from higher operating income and lower interest expenses.

**Net Income Per Share - Diluted**: $1.75, up from $1.42 in the prior year, reflecting the overall improvement in net income and share repurchase activities.

**Business Highlights**

**Revenue Segments**

* **Healthcare Segment**: Reported revenues of $976,044 for the three months ended December 31, 2024, with capital equipment, consumables, and service contributing significantly.
* **AST Segment**: Generated $258,144 in revenues, primarily from service offerings.
* **Life Sciences Segment**: Reported $136,382 in revenues, with a notable contribution from consumables and service.

**Geographical Performance**

* **United States**: Remains the largest market, contributing $1,002,586 to total revenues for the three months ended December 31, 2024.
* **Other Locations**: Including Ireland, also showed strong performance, with revenues of $343,867 and $24,117, respectively.

**New Product Launches**

During the reporting period, STERIS expanded its product offerings in the Healthcare segment by acquiring surgical instrumentation and sterilization container assets from Becton, Dickinson and Company, integrating these into its existing portfolio.

**Future Outlook**

Management anticipates continued growth in the Healthcare and AST segments, driven by increased demand for infection prevention and sterilization services. The company is also focused on enhancing profitability and efficiency through its restructuring plan, which is expected to be substantially complete by the end of fiscal 2025.

SEC Filing: [STERIS plc [ STE ] - 10-Q - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/1757898/000175789825000002/ste-20241231.htm)

[TradingView](https://www.tradingview.com/news/tradingview:1c820718c243c:0-steris-plc-sec-10-q-report/)
